The bcr-abl1 fusion protein enhances cell survival and exerts antiapoptotic activity in CML cells, thus mediating resistance to apoptosis [3–8]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.